A new review published in Frontiers argues that standard one-dimensional microbiological assays can no longer carry the weight of preclinical testing for bioactive textiles — fabrics engineered to interact with the human skin microbiome.

The paper, titled "From 1D microbiological assays to 3D advanced skin models: enhancing preclinical strategies to unravel the impact of bioactive textiles on the human skin microbiome," lays out a case for moving preclinical evaluation toward three-dimensional advanced skin models that better approximate living human skin.

Why do 1D assays fall short for bioactive textiles?

Traditional microbiological assays grow single microbial strains on flat culture media. That format tells you whether a compound kills or inhibits a microbe in isolation. It tells you very little about what happens when a bioactive textile sits against a living, layered, microbially diverse skin surface for hours at a time.

The skin microbiome doesn't behave as a set of independent monocultures. Communities interact with each other, with host cells and with the material itself. A flat-plate result can't capture that dynamics — which is precisely the gap the review targets.

What do 3D advanced skin models offer?

Three-dimensional reconstructed skin models build structure: layered epidermal and, in some configurations, dermal compartments, with living human cells and, increasingly, defined microbial communities seeded onto or into the tissue. That architecture lets researchers test how a textile's bioactive finish behaves against something far closer to real skin than a petri dish.

For dermatology, the stakes run past methodological tidiness. Bioactive textiles are moving into consumer and clinical markets with claims that touch barrier function, dysbiosis and microbial balance — and those claims deserve testing systems that can actually detect effects on a microbiome in a skin-like context.

The review frames the progression as a staged preclinical strategy: start with the simple assays for screening, then escalate candidates through increasingly complex 3D systems before any human exposure.

What does this mean for dermatology practice?

Clinicians field questions about antimicrobial, prebiotic and other "bioactive" fabrics from patients with eczema, acne and sensitive skin. Most of those patients assume somebody tested the product against real skin. In many cases, the supporting data stops at monoculture inhibition zones.

A testing hierarchy built around 3D skin models would give regulators, manufacturers and clinicians a more honest read on whether a given textile genuinely shifts the skin microbiome, and in which direction. It also sets up a clearer separation between marketing language and evidence class — the same discipline dermatology already applies to cosmeceutical actives.

The review's broader message: as biofunctional textiles multiply, preclinical methodology has to scale with them. Expect 3D microbiome-competent skin models to become a standard checkpoint between bench assays and human wear trials in the textile-testing pipeline.